Consistent with the TCGA database expression trend, FASN expression was significantly higher in COAD, UCEC, and PAAD, and demonstrated a decreasing trend in comparison with normal samples in BRCA, ovarian cancer, GBM, liver cancer, and lung cancer (Figure 1D). This evidence concerns the gene FASN and glioblastoma.